Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Jubilant and Mnemosyne Pharmaceuticals Announce Drug Discovery Collaboration

February 21, 2012

BANGALORE, India, February 21, 2012 /PRNewswire/ –

Jubilant Biosys Limited, Bangalore announced today that they have entered into drug
discovery collaboration with Mnemosyne Pharmaceutical Inc, Providence, Rhode Island that
will seek to identify preclinical candidates in the area of neuropsychiatric diseases. The
collaboration will focus on developing subunit selective NMDA receptor modulators (SNRMs)
that Mnemosyne has identified. The alliance shall initially span a period of 2 years and
may be extended on mutual consent across other therapeutic programs as well.

The multi-target program agreement will be enabled by the expertise of Mnemosyne in
NMDA receptor pharmacology and supported by Jubilant’s translational center in Malvern,
Pennsylvania and by scientists from Jubilant’s India based facilities. The collaboration
will leverage the capabilities of the companies across medicinal chemistry, NMDA receptor
pharmacology, electrophysiology, computational chemistry and DMPK and in vivo pharmacology
as appropriate in progressing promising compounds that have been identified by Mnemosyne.
Under the terms of the alliance agreement, Mnemosyne will exclusively own all IP generated
and shall be responsible for clinical development and commercialization.

Commenting on this achievement, Sri Mosur, CEO & President, Global Drug Discovery &
Development, Jubilant said: “We are pleased to collaborate with Mnemosyne Pharmaceuticals
Inc, on the SNRM platform,We are excited about the Mnemosyne programs and enthused that
our ion channel expertise in Malvern, Pennsylvania supported by already demonstrated
capabilities in India will be leveraged in this collaboration to deliver optimal outcomes
in the difficult area of neuroscience research. This creative alliance further
demonstrates Jubilant’s commitment to global R&D in enabling early discovery research
towards optimal commercialization.”

Commenting on the collaboration Mnemosyne CEO, Dr. Kollol Pal said that “Mnemosyne is
very impressed with the integrated chemistry and biology expertise that has been assembled
by Jubilant, particularly in the area of ion channels and neuroscience. We are looking
forward to a successful collaboration with Jubilant that will produce first-in-class drugs
that address the unmet medical need in neuropsychiatric diseases such as schizophrenia and
Alzheimer’s disease.”

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd,
headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and
development solutions to the global pharmaceutical industry. It is a pioneer in
collaborative discovery research and development and is engaged in multiple partnerships
with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

About Mnemosyne

Mnemosyne Pharmaceuticals, Inc. is a privately-held, biotechnology company focused on
the discovery and development of small molecule therapeutics for the neuropsychiatry
market. The company’s drug discovery efforts are focused on targeting the NMDA receptor,
which is known to be the “master” switch for learning and memory. Mnemosyne’s lead program
is for schizophrenia, and the company is exploring additional indications including
Alzheimer’s disease, recovery from stroke and traumatic brain injury and attention
deficit/hyperactivity disorder.

http://www.mnemosynepharma.com

SOURCE Jubilant Biosys Ltd


Source: PR Newswire